HER2阳性转移性乳腺癌治疗年度进展

doi:10.3969/j.issn.1009?976X.2018.02.001

岭南现代临床外科 ›› 2018, Vol. 18 ›› Issue (02): 123-127.DOI: 10.3969/j.issn.1009?976X.2018.02.001

• 述评 • 下一篇

HER2阳性转移性乳腺癌治疗年度进展

柴洁，姚和瑞*

中山大学孙逸仙纪念医院

通讯作者: 姚和瑞
基金资助:
国家自然科学基金;国家自然科学基金;国家自然科学基金;广东省自然科学基金;广州市科技计划;广州市科技计划

Annual progress of HER2 positive metastatic breast cancer

CHAI Jie, YAO Herui

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Online:2018-04-20 Published:2018-04-20
Contact: YAO Herui

摘要/Abstract

摘要： 乳腺癌是我国女性发病率最高的恶性肿瘤，其中HER2阳性转移性乳腺癌在晚期乳腺癌占比为25%~30%。HER2阳性乳腺癌患者预后差，如何提高HER2阳性转移性乳腺癌的治疗效果，包括优化靶向治疗、化疗药物的选择、后线治疗的策略等具有重要的临床意义。本文基于2017年各大乳腺癌会议，针对HER2阳性转移性乳腺癌在临床中的常见问题，阐述HER2阳性转移性乳腺癌治疗策略的新进展。

关键词: HER2阳性, 转移性乳腺癌, 靶向优化, 年度进展

Abstract: Breast cancer is one of the most common malignant disease in China. HER2 positive meta?static breast cancer accounted for 25% to 30%. The prognosis of HER2 positive metastatic breast cancer is poor, how to improve the therapeutic effect of HER2 positive metastatic breast cancer have vital clinical-significance, including optimize targeted therapy, selection of chemotherapy and strategy beyond first-line therapy. This article based on the 2017 breast cancer conference and reviewed the latest progress of HER2 positive metastatic breast cancer.

Key words: annual progress, HER2 positive, metastatic breast cancer, targeted optimization

中图分类号:

R737.9

柴洁，姚和瑞*. HER2阳性转移性乳腺癌治疗年度进展[J]. 岭南现代临床外科, 2018, 18(02): 123-127.

CHAI Jie, YAO Herui. Annual progress of HER2 positive metastatic breast cancer[J]. Lingnan Modern Clinics in Surgery, 2018, 18(02): 123-127.

[1]	桂秀娟, 赵健丽, 汪颖, 柴洁, 丁林潇潇, 姚和瑞. 伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例[J]. 岭南现代临床外科, 2021, 21(06): 675-678.
[2]	彭江云, 姚伟城, 王永强, 邓伟溪. HER2阳性乳腺癌治疗及耐药性研究进展[J]. 岭南现代临床外科, 2020, 20(02): 243-253.

HER2阳性转移性乳腺癌治疗年度进展

Annual progress of HER2 positive metastatic breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics